Evommune (EVMN) Change in Account Payables (2024 - 2026)

Evommune (EVMN) has reported Change in Account Payables for 3 consecutive years, with -$3.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Account Payables fell 442.55% year-over-year to -$3.7 million; the TTM figure through Mar 2026 stood at $2.3 million (changed N/A YoY), while the FY2025 annual figure was -$837000.0, down 112.87% from the prior year.
• Change in Account Payables slipped to -$3.7 million in Q1 2026 per EVMN's latest filing, from $3.9 million in the prior quarter.
• Across five years, Change in Account Payables topped out at $3.9 million in Q4 2025 and bottomed at -$3.7 million in Q1 2026.
• Historically, Change in Account Payables has averaged $566250.0 across 3 years, with a median of $1.1 million in 2024.
• Annual changes were most pronounced in 2025 — Change in Account Payables soared 34.93% — and 2026, when it tumbled 442.55%.
• Evommune's Change in Account Payables stood at $2.9 million in 2024, then surged by 34.93% to $3.9 million in 2025, then slumped by 197.35% to -$3.7 million in 2026.
• Business Quant data shows EVMN's Change in Account Payables at -$3.7 million in Q1 2026, $3.9 million in Q4 2025, and -$691000.0 in Q1 2025.